rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Merus NV forum geopend

1.054 Posts
Pagina: «« 1 ... 15 16 17 18 19 ... 53 »» | Laatste | Omlaag ↓
  2. nelis h 11 maart 2018 17:08

    • nelis h

      Lid sinds: 01 jan 2000

      Laatste bezoek: 10 jan 2025

    • Aanbevelingen

      Ontvangen: 713

      Gegeven: 734

    •    Aantal posts: 3.132

    beurswaarde moet eerst naar minimaal een miljard voor ik uit stap.
    een ArgenX-je kan ik wel een jaartje op wachten
  4. [verwijderd] 13 maart 2018 13:02

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Goed nieuws uiteindelijk bepaald de IP mede de waarde

    UTRECHT, The Netherlands, March 13, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that it has expanded its intellectual property portfolio with two newly issued U.S. Patents. The first covers clinical drug candidate MCLA-117, a Biclonics® that binds to CD3 and CLEC12A, and the second concerns Merus’ Spleen to Screen® technology that permits efficient screening of common light chain antibodies for generating Biclonics® lead candidates.

    On March 13, 2018, the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 9,914,777 (’777 patent), entitled “Human CD3 Binding Antibody”, covering MCLA-117, a Biclonics® that is designed to bind to CD3, a cell-surface molecule present on all T-cells, and to CLEC12A, a first-in-class target, expressed on the tumor cells and tumor stem cells of patients with acute myeloid leukemia (AML). Due to its prevalence in AML and restricted expression on some normal hematopoietic cells, we believe CLEC12A represents an attractive molecule for targeted therapy. The claims of the ‘777 patent concern Merus’ Biclonics®, and MCLA-117 in particular, that engage T-cells with tumor cells by targeting CD3 and a tumor-antigen, including CLEC12A. MCLA-117 is currently being studied in an ongoing Phase 1, first-in-human, dose escalation clinical trial in Europe in AML patients with relapsed or refractory disease, and obtained acceptance in February 2018 by the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application filed earlier this year.

    On March 6, 2018, the USPTO also granted U.S. Patent No. 9,908,946 (’946 patent) entitled, “Generation of Binding Molecules,” which concerns Merus’ proprietary Spleen to Screen® technology, a part of its Biclonics® technology platform. The ‘946 patent claims techniques to efficiently screen panels of common light chain antibodies, designed to allow Merus to rapidly identify and generate therapeutic candidates with differentiated modes of action.

    “The issuance of Merus’ first U.S. Patent covering MCLA-117, marks yet another milestone in the advancement of this promising clinical candidate, which, along with the patent issuance covering our Spleen to Screen® technology, adds further intellectual property protection related to our clinical candidates and bispecific antibody platform based on our proprietary Biclonics® technology,” said Dr. Ton Logtenberg, Chief Executive Officer of Merus.

    As of March 13, 2018, Merus’ patent portfolio related to its bispecific antibody candidate MCLA-117 consists of additional pending applications in the U.S., Europe and an array of foreign countries. Merus has also obtained patents around the globe, including throughout Europe, Asia, Australia and the U.S. related to its Spleen to Screen® technology, with other applications still pending in the U.S. and abroad.

    These two recent issuances by the USPTO reported here bolster Merus’ substantial patent estate related to the panoply of Biclonics® technologies, including transgenic rodents, production of antibody libraries, screening methods, Fc engineering, antibody host cell expression and preclinical and clinical bispecific antibody candidates.
  6. Pokerface 14 maart 2018 12:08

    • Pokerface

      Lid sinds: 27 mrt 2001

      Laatste bezoek: 09 apr 2025

    • Aanbevelingen

      Ontvangen: 1019

      Gegeven: 1235

    •    Aantal posts: 3.960

    MERUS ANNOUNCES ONO PHARMACEUTICALS EXERCISE OF ITS OPTION FOR NEW RESEARCH AND LICENSE AGREEMENT TO GENERATE BISPECIFIC ANTIBODY TARGETING AUTOIMMUNE DISEASES

    UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ono Pharmaceutical Co., LTD. (Osaka, Japan, ‘Ono’) has exercised its option under an agreement executed in April 2014 to enter into a new research and license agreement utilizing Merus’ proprietary Biclonics® technology platform to generate a bispecific antibody that binds to a combination of targets designed for the treatment of autoimmune diseases.

    “Ono’s decision to exercise its option builds on the success to date of the original collaboration we entered into in 2014,” said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. “As we continue to advance and expand Merus’ proprietary pipeline of innovative therapeutic candidates in oncology, we are very excited to work with a collaborator such as Ono to leverage our Biclonics® technology platform to develop therapeutics for other disease areas with significant unmet medical needs.”

    "We highly value Merus’ proprietary drug discovery technology which effectively generates full-length human bispecific antibody therapeutics," said Hiromu Habashita, Ph.D., Corporate Officer, and Executive Director of Discovery & Research of Ono. "We are glad to expand our collaboration and look forward to realizing the next generation of high value treatments in autoimmune disease area.”

    In April 2014, Merus and Ono entered into a research and license agreement to jointly develop bispecific antibody therapies for autoimmune diseases. In 2016, Ono selected a lead bispecific antibody candidate that it intends to advance into clinical testing, which triggered a milestone payment to Merus. By exercising its option under the terms of the first agreement, Ono has agreed to fund research activities at Merus that will generate candidate Biclonics® for the new program. Merus has granted Ono worldwide exclusive rights to develop, manufacture, and commercialize the resulting products developed through the collaboration.

    Consistent with the terms of Merus’ 2014 agreement, under the new agreement, Merus will receive an undisclosed upfront payment. Merus is also eligible to receive milestone payments upon achievement of specified research and clinical development milestones. For products commercialized under this agreement, if any, Merus is also eligible to receive a mid-single digit royalty on net sales.

    Bron: phoenix.corporate-ir.net/phoenix.zhtm...
  18. forum rang 6 Tom3 15 maart 2018 22:55

    • Tom3

      Lid sinds: 25 jan 2015

      Laatste bezoek: 09 apr 2025

    • Aanbevelingen

      Ontvangen: 2934

      Gegeven: 633

    •    Aantal posts: 11.419

    quote:

    fly like an eagle schreef op 14 maart 2018 12:33:

    Zeer goed nieuws!
    De beurs heeft het echter allemaal voor kennisgeving aangenomen:-5,6% vandaag. Ook hier gaat men pas in actie komen als men bij wijze van spreken de dollarbiljetten ruiken kan. Wanneer komen nu die fase 1 resultaten mbt #117? Ze wilden zeker eerst het patent veilig stellen, waarom trouwens?
1.054 Posts
Pagina: «« 1 ... 15 16 17 18 19 ... 53 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.154
AB InBev 2 5.544
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.435
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.925
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 193
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.885
Aedifica 3 927
Aegon 3.258 323.193
AFC Ajax 538 7.092
Affimed NV 2 6.306
ageas 5.844 109.908
Agfa-Gevaert 14 2.074
Ahold 3.538 74.355
Air France - KLM 1.025 35.313
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.056
Alfen 16 25.463
Allfunds Group 4 1.522
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.211
AMG 972 134.665
AMS 3 73
Amsterdam Commodities 305 6.753
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 501
Antonov 22.632 153.605
Aperam 92 15.101
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.808
Arcelor Mittal 2.035 321.068
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.372
Aroundtown SA 1 221
Arrowhead Research 5 9.752
Ascencio 1 30
ASIT biotech 2 697
ASMI 4.108 39.684
ASML 1.767 111.871
ASR Nederland 21 4.521
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.294
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.462